To connect a sign in method the email must match the one on your Crikey account.
Contact us on: support@crikey.com.au
Australians are bragging online that they're able to legally take ivermectin thanks to a study given approval by a controversial institute.
Australians are br
The European Medicines Agency (EMA) advises against the use of ivermectin in the treatment of COVID-19 outside carefully designed clinical studies.The agency draws this conclusion based on available, recent scientific data that does not support the use of this drug.The advice was prompted by rece
Newsletter Subscribe Now See Details
I took this photo of a beef cow that had just calved in a drylot holding area. She is in good shape and health so I would expect that once her newborn calf is up on wobbly legs, it will get its first taste of colostrum. Within the next few hours,
Hi, what are you looking for?
“Tylosin Market” Insights 2022 By Types (Tylosin Tartrate,Tylosin Phosphate,Tylosin Base,), Applications (Animal Feed Additives,Animal Drugs,), Regions and Forecast to 2028. The global Tylosin market size is projected to reach multi million by 20
Hi, what are you looking for?
“Tylosin Market” Insights 2022 By Types (Tylosin Tartrate,Tylosin Phosphate,Tylosin Base,), Applications (Animal Feed Additives,Animal Drugs,), Regions and Forecast to 2028. The global Tylosin market size is projected to reach multi million by 20
Sheep and goat producers almost always cite worms as the primary health problem affecting their livestock.
While small ruminants can be affected by many different kinds of parasites, the primary one affecting them during the summer grazing season is the barber pole worm (Haemonchus conto
The compound feed market is projected to register a CAGR of 4. 1% during the forecast period (2022-2027). The increased demand for compound feed across the world is highly hampered by the COVID-19 pandemic, resulting in supply chain disruption restricting the product trade.
New York, Jul
Posted by admin on Jul 17th, 2022
Avivagen Inc. (CVE:VIV – Get Rating) shares reached a new 52-week low during mid-day trading on Friday . The company traded as low as C$0.18 and last traded at C$0.18, with a volume of 12500 shares traded. The stock had previously clo
Posted by admin on Jul 17th, 2022
Avivagen Inc. (CVE:VIV – Get Rating) shares reached a new 52-week low during mid-day trading on Friday . The company traded as low as C$0.18 and last traded at C$0.18, with a volume of 12500 shares traded. The stock had previously clo
Permanent link to this press release:
Delete press release Edit press rele